Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00712712|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : July 10, 2008
Last Update Posted : December 15, 2009
RATIONALE: Morphine may reduce pain in patients who have undergone radiofrequency ablation to remove bone metastases.
PURPOSE: This phase II trial is studying how well morphine works after radiofrequency ablation of painful bone metastases in patients with cancer.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Cancer Pain Unspecified Adult Solid Tumor, Protocol Specific||Drug: acetaminophen Drug: morphine sulfate Other: questionnaire administration Procedure: quality-of-life assessment Procedure: radiofrequency ablation||Phase 2|
- Measure the efficacy of morphine sulfate at 8 weeks after radiofrequency ablation (RFA) of bone metastases.
- Assess minimum and average pain and analyze use of morphine sulfate before and after RFA.
- Determine disease progression by CT scan of bone.
- Evaluate the percentage of relief associated with RFA, specifically patient satisfaction, quality of life, anxiety, depression, and physical performance during RFA.
- Assess complications and side effects related to RFA and the evolution of possible side effects associated with morphine sulfate therapy.
OUTLINE: This is a multicenter study.
Patients complete a pain questionnaire over 1 week before undergoing radiofrequency ablation (RFA). Patients also complete questionnaires about pain, physical performance, quality of life (QOL), and anxiety at baseline.
Bone metastases are removed by radiofrequency ablation (RFA). After surgery, patients receive acetaminophen and patient-controlled analgesic (PCA) morphine sulfate. PCA morphine sulfate continues with a dose increase of 50% bolus every 24 hours. Patients with maximum pain less than or equal to that at inclusion receive standard morphine sulfate therapy instead.
Data concerning the total dose of PCA morphine sulfate; minimum, average, and maximum pain intensity; side effects and complications of RFA; and total dose of morphine sulfate (or equivalent) is collected daily.
Pain is assessed at 4 and 8 weeks after RFA. Patients complete follow-up questionnaires about physical performance, QOL, and anxiety at 12 weeks. Patients also undergo a CT scan at 12 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||63 participants|
|Primary Purpose:||Supportive Care|
|Official Title:||Evaluation of the Effectiveness of the Radiofrequency Ablation for Reducing Refractory Pain From Bone Metastases|
|Study Start Date :||October 2007|
|Estimated Primary Completion Date :||December 2010|
- Maximum pain level decreased by ≥ 2 points at 8 weeks after radiofrequency ablation (RFA)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00712712
|Bordeaux, France, 33076|
|Contact: Contact Person 33-556-333-333 email@example.com|
|Study Chair:||Florence Dixmerias, MD||Institut Bergonié|